摘要
抗血管生成药物的抗肿瘤机制与化疗药物不同,细胞毒药物的生物标志物对抗血管生成药物来说未必适用,因此寻找和选择有关的生物标志物对于抗血管生成治疗来说十分必要。目前一些与血管生成相关的蛋白质、内皮细胞、微血管密度等已在抗肿瘤血管生成的研究中越来越受到重视。本文将围绕以上这些与抗血管生成治疗相关的生物标志物的检测手段,以及它们在剂量指示、早期临床受益、耐药性出现和二线治疗选择等方面的应用进行综述。
The anti-tumor mechanisms of anti-angiogenic drugs and cytotoxic agents are different. Since biomarkers for cytotoxie agents are not optimal for anti-angiogenic drugs,it is necessary to search biomarkers for the anti-angiogenesis therapy. Angiogenesis related biomarkers, such as circulating proteins, circulating endothelial cells （CEC） and microvessel density （MVD）, have been received more and more attention. This review will focus on detection of these biomarkers, and their application in selecting dosage, evaluating early clinical benefit, predicting emergence of resistance and selecting second-line treatments, etc.
出处
《药学服务与研究》
CAS
CSCD
2009年第3期186-190,共5页
Pharmaceutical Care and Research
